Literature DB >> 9764957

Therapeutic drug monitoring--antiepileptic drugs.

M J Eadie1.   

Abstract

AIMS: To provide a brief critical review of the basis and contemporary practice of monitoring the concentrations of antiepileptic drugs in biological fluids.
METHODS: The review is based on literature data and observations from clinical practice.
RESULTS: As experience has accumulated, monitoring of antiepileptic drug concentrations has come to be applied mainly to certain of the drugs when present in whole plasma. For these drugs there is a reasonably established relationship between drug concentrations and biological effects, but attention still needs to be paid to issues such as the timing of the measurements in relation to drug intake, the presence or absence of steady-state conditions, the presence in plasma of active metabolites and possible nonlinear pharmacokinetics of particular agents e.g. phenytoin.
CONCLUSIONS: Plasma antiepileptic drug concentration monitoring is coming to be used in a more thoughtful and critical manner. Lack of adequate knowledge of matters such as the relationship between the plasma concentrations and antiepileptic and toxic effects of the drugs, not only the newer, but also the longer established ones, in particular clinical situations, remains more important than deficiencies in analytical methodology in limiting the clinical usefulness of antiepileptic drug concentration monitoring.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764957      PMCID: PMC1873678          DOI: 10.1046/j.1365-2125.1998.00769.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  64 in total

1.  Determination of diphenylhydantoin and phenobarbital in small amounts of serum.

Authors:  O SVENSMARK; P KRISTENSEN
Journal:  J Lab Clin Med       Date:  1963-03

2.  Studies on 5, 5'-diphenylhydantoin (dilantin) in animals and man.

Authors:  W A DILL; A J GLAZKO; A KAZENKO; L M WOLF
Journal:  J Pharmacol Exp Ther       Date:  1956-11       Impact factor: 4.030

3.  Assay and pharmacokinetics of clonazepam in humans.

Authors:  J Naestoft; M Lund; N E Larsen; E Hvidberg
Journal:  Acta Neurol Scand Suppl       Date:  1973

4.  Erythrocyte uptake and plasma binding of diphenylhydantoin.

Authors:  D Kurata; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

5.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

6.  Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.

Authors:  H Kutt; F McDowell
Journal:  JAMA       Date:  1968-03-11       Impact factor: 56.272

7.  Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects.

Authors:  J T Bigger; D H Schmidt; H Kutt
Journal:  Circulation       Date:  1968-08       Impact factor: 29.690

8.  Influence of ethylphenacemide on serum levels of other anti-epileptic drugs.

Authors:  J W Huisman; M W van Heycop ten Ham; C H van Zijl
Journal:  Epilepsia       Date:  1970-06       Impact factor: 5.864

9.  Spectrophotometric determination of diphenylhydantoin.

Authors:  J E Wallace
Journal:  J Forensic Sci       Date:  1966-10       Impact factor: 1.832

10.  Plasma protein binding of carbamazepine.

Authors:  W D Hooper; D K Dubetz; F Bochner; L M Cotter; G A Smith; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

View more
  8 in total

Review 1.  Therapeutic drug monitoring in a developing country: an overview.

Authors:  N J Gogtay; N A Kshirsagar; S S Dalvi
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 3.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

4.  Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.

Authors:  Juseop Kang; Yoo-Sin Park; Shin-Hee Kim; Sang-Hyun Kim; Min-Young Jun
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

Review 5.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  [Therapeutic drug monitoring of three antiepileptic drugs - Back on twenty years of experience].

Authors:  Samira Serragui; Fatima Zalagh; Driss Soussi Tanani; Lahcen Ouammi; Latifa Ait Moussa; Narjis Badrane; Rachida Soulaymani Bencheikh
Journal:  Pan Afr Med J       Date:  2016-09-19

7.  Management of Epileptic Seizures in Disorders of Consciousness: An International Survey.

Authors:  Marie-Michèle Briand; Nicolas Lejeune; Nathan Zasler; Rita Formisano; Olivier Bodart; Anna Estraneo; Wendy L Magee; Aurore Thibaut
Journal:  Front Neurol       Date:  2022-01-11       Impact factor: 4.003

Review 8.  On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug Monitoring.

Authors:  Barbara Sanavio; Silke Krol
Journal:  Front Bioeng Biotechnol       Date:  2015-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.